NanoString sales and marketing update

NanoString said Medicare administrative contractor Palmetto GBA LLC (Columbia, S.C.) issued a final local coverage determination (LCD) recommending coverage of NanoString’s Prosigna Breast Cancer Prognostic Gene Signature Assay. The LCD takes effect Oct. 1. Palmetto will cover the test for postmenopausal patients with estrogen receptor (ER)-positive, lymph node-negative, stage I or II breast cancer and ER-positive, lymph node-positive, stage II breast cancer. ...